for people ages 18 years and up (full criteria)
at San Francisco, California
study started
estimated completion
Principal Investigator
by Priscilla Hsue
Photo of Priscilla Hsue
Priscilla Hsue



The purpose of this study is to describe the epidemiology of pulmonary hypertension in individuals with HIV infection and to investigate its pathogenesis. We propose to conduct a prospective observational cohort study to determine the association between highly active antiretroviral therapy (HAART) and viral suppression in HIV-infected patients who have been identified to have pre-clinical pulmonary hypertension (Aim 1). In addition, we will investigate the mechanistic role of the HIV-1 Nef protein and HHV-8 infection in the development and progression of pulmonary hypertension in individuals with HIV (Aim 2). We will also investigate endothelial function in HIV-infected patients with pulmonary hypertension (Aim 3).


HIV Infection Pulmonary Hypertension Endothelial Function HIV Infections antiretroviral medication Treatment Experienced Infection Communicable Diseases Acquired Immunodeficiency Syndrome Hypertension, Pulmonary Hypertension


You can join if…

Open to people ages 18 years and up

  1. Infection with HIV greater than 6 months in duration
  2. Right heart catheterization showing PASP > 30mm Hg
  3. Ability to provide reliable history of HIV medications or has received the majority of medical care from San Francisco General Hospital with available records of medical treatment.
  4. Ability to participate in follow-up for the duration of the study.

You CAN'T join if...

  1. Known significant cardiovascular disease, including clinically significant valvular heart disease, congenital heart disease, current or prior symptomatic coronary disease, or known cardiomyopathy.
  2. Any known pulmonary disease that could potentially cause pulmonary hypertension.
  3. A pO2 by pulse oximetry below 90% on room air.
  4. Obstructive sleep apnea.
  5. Known collagen vascular disease.
  6. History of anorexigen use
    1. Age less than 18 years old.
    1. Other co-morbidities for which the investigators, in conjunction with the primary care provider, believe render the participant with an expected survival of 6 months or less.


  • University of California, San Francisco
    San Francisco California 94110 United States

Lead Scientist at UCSF

  • Priscilla Hsue
    Professional Experience: Dr. Hsue trained in Internal Medicine in the Molecular Medicine Training Program at UC San Francisco and in Cardiovascular Medicine at UC San Francisco. She served as Chief Cardiology Fellow during this time. She has been on the faculty in the Department of Medicine at San Francisco General Hospital since 2002.


in progress, not accepting new patients
Start Date
Completion Date
University of California, San Francisco
Study Type
Last Updated